🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

647 results for “Les” Clear

  1. Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Avastin 25 mg/ml concentrate for solution for infusion., Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Zejula 100 mg hard capsules, Zejula 100 mg hard capsules, Zejula 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion.

    TESARO Bio Netherlands B.V.

    Ovarian Neoplasms

    phase 2 small molecule active

    1 trial

  2. Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles

    Regeneron UK Limited

    Merkel Cell Carcinoma, Stage I

    phase 2 small molecule active

    1 trial

  3. Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Uterine Cervical Neoplasm

    phase 2 small molecule active

    1 trial

  4. Colesevelam hydrochloride-MMX® modified-release placebo tablets, Colesevelam hydrochloride-MMX® 900 mg modified-release tablets

    Cosmo Technologies Ltd

    bile acid diarrhoea (BAD)

    phase 2 small molecule active

    1 trial

  5. Contingency Management-Family Engagement (CM-FAM)

    BRIGHT MINDS BIOSCIENCES INC.

    Adolescent Substance Use

    phase 2 other completed

    1 trial

  6. Convalescent Plasma

    United Therapeutics Europe Ltd

    COVID-19

    phase 2 mab terminated

    1 trial

  7. Cyproterone acetate/ethinylestradiol (CPA/EE)

    Universal Integrated

    Polycystic Ovarian Syndrome

    phase 2 small molecule completed

    1 trial

  8. DASATINIB, Dasatinib, dasatinib, dasatinib

    Bristol-Myers Squibb Australia Pty Ltd

    Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib

    phase 2 small molecule active

    1 trial

  9. DS-8201a

    AstraZeneca AB

    Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology

    phase 2 small molecule active

    1 trial

  10. DURVALUMAB, Ceralasertib

    Istituto Gentili S.r.l.

    Stage III NSCLC patients with loco-regional relapse > 12 months from the end of CRT +/- < 3 metastatic lesions after PACIFIC regimen or PACIFIC-like regimens (concurrent or sequential chemo-radiotherapy followed by maintenance durvalumab), regardless of PD-L1 status, but without EGFR, HER-2 or MET exon14 skipping mutations, ALK, ROS1, RET or NTRK rearrangements.

    phase 2 small molecule active

    1 trial

  11. Dexamethasone 4 mg tablets, Cytarabine 20 mg/ml Solution for Injection or Infusion, Calquence 100 mg hard capsules, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Histergan Tablets, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, Mesna Injection, Methylprednisolone 1000 mg powder and solvent for solution for injection/infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Panadol 50

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  12. Dexamethasone Tablets BP 2.0mg, Imnovid 3 mg hard capsules, Dexamethason 4 mg JENAPHARM®, teclistamab, teclistamab, Privigen 100 mg/ml solution for infusion, Fortecortin® 2 mg Tabletten, Pomalidomide, Dexamethason 8 mg GALEN® Tabletten, Pomalidomide, Privigen 100 mg/ml solution for infusion, Imnovid 2 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Pomalidomide, Pomalidomide, Privigen 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, Im

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  13. E7386, Doxorubicin EBEWE 2 mg/ml koncentratas infuziniam tirpalui, E7386, Паклитаксел Ебеве 6 mg/ml концентрат за инфузионен разтвор, Paclitaxel Aurobindo 6 mg/ml concentrato per soluzione per infusione, Doxorubicina Aurobindo 2 mg/ml concentrato per soluzione per infusione, LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules

    Eisai Co.,

    Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumor

    phase 2 small molecule active

    1 trial

  14. EPI-7386, Xtandi - 40 mg soft capsules

    Lacuna Pharma Pty Ltd

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  15. ETIDRONATE DISODIUM ORAL CAPSULES 400 MG PLACEBO, ETIDRONATE DISODIUM ORAL CAPSULES 400 MG

    Disc Medicine

    Fahr's disease, Fahr's syndrome

    phase 2 small molecule active

    1 trial

  16. Early recognition of progressive lung fibrosis in systemic rheumatic diseases: a characterization of the pulmonary environment through extracellular vesicles, advanced and functional imaging

    Fondazione Telethon ETS

    Patients with connective tissue diseases at high risk of interstial lung disease

    phase 2 other active

    1 trial

  17. Encorafenib, Mektovi 15 mg film-coated tablets, Braftovi 75 mg hard capsules, Braftovi 50 mg hard capsules, Mektovi 15 mg film-coated tablets, Braftovi 75 mg hard capsules, Braftovi 50 mg hard capsules

    Pfizer Australia Pty Ltd

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. Enteric coated sevelamer

    Sanofi Pasteur

    Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  19. Epidyolex 100 mg/ml oral solution

    Pari Pharma GmbH

    Children and adolescents with severe neurodevelopmental disorders

    phase 2 small molecule active

    1 trial

  20. Erbitux 5 mg/mL solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, Braftovi 75 mg hard capsules

    The George Institute

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  21. Etripamil

    Milestone Pharmaceuticals

    Paroxysmal Supraventricular Tachycardia (PSVT)

    phase 2 small molecule completed

    1 trial

  22. Etripamil

    Milestone Pharmaceuticals

    Atrial Fibrillation

    phase 2 small molecule completed

    1 trial

  23. Evinacumab

    Regeneron UK Limited

    Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  24. FRUZAQLA 5 mg hard capsules, FLUOROURACIL, FOLINIC ACID, FLUOROURACIL, IRINOTECAN, OXALIPLATIN, Avastin 25 mg/ml concentrate for solution for infusion., FRUZAQLA 1 mg hard capsules

    CERO THERAPEUTICS HOLDINGS, INC.

    métastatique colorectal cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources